Stocks Market

Stocks Market

Morocco's Laprophan Expands Pharma Empire with Polymedic Acquisition Deal

<p>Moroccan pharmaceutical giant Laprophan has signed a definitive agreement to acquire 100% of Corporate Investment Holding (CIH), the parent company of Polymedic, marking its fourth major acquisition since 2020. The deal, notified to the Competition Council for regulatory approval, would add Polymedic's 280 employees, 9,600 m² Casablanca manufacturing facility, and portfolio of 138 marketing authorizations covering over 200 products across 12 therapeutic areas to Laprophan's growing footprint. Financial terms remain undisclosed.</p><p>This strategic move continues Laprophan's aggressive expansion strategy that has already seen it acquire Amanys Pharma, Botanic Pharma, and Swiss-based Rivopharm. The combined entity would boast approximately 1,450 employees, four production sites across Morocco and Switzerland, commercial presence in over 50 countries, and more than 1,300 marketing authorizations spanning 15 therapeutic areas with annual production capacity exceeding 180 million units.</p>

October 21st, 2026
3 min read
By boursenews.ma

Listen to this article

Unlock audio versions of premium articles and more with a Pro subscription.

Laprophan Continues Acquisition Spree with Polymedic Deal

Morocco's leading pharmaceutical group Laprophan has announced the signing of a binding agreement to acquire the entirety of Corporate Investment Holding (CIH), the holding company that controls Polymedic, one of the country's established domestic drug manufacturers. The announcement, made on October 21, 2026, signals the continuation of an ambitious consolidation strategy that has reshaped the Moroccan pharmaceutical landscape over the past six years.

Deal Structure and Regulatory Path

The transaction covers 100% of CIH's share capital. As required by Moroccan competition law, the proposed acquisition has been formally notified to the Conseil de la concurrence (Competition Council), whose prior approval constitutes a condition precedent to closing. Laprophan's statement did not disclose the purchase price or valuation multiples, nor did it provide a targeted timeline for regulatory clearance and final completion.

Polymedic: A Strategic Asset

Founded in 1964, Polymedic brings substantial industrial and commercial assets to the table:

  • Workforce: Approximately 280 employees
  • Manufacturing footprint: A 9,600 m² production facility in Casablanca
  • Regulatory portfolio: 138 marketing authorizations (AMMs) covering more than 200 marketed products
  • Therapeutic breadth: Presence across 12 therapeutic areas, with notable strength in dermatology, central nervous system (CNS), and cardiovascular treatments
  • Commercial infrastructure: A dedicated medical promotion subsidiary, Promaceutique

Strategic Rationale: Portfolio Complementarity and Scale

Laprophan frames the acquisition as a natural extension of its external growth strategy, highlighting several value-creation levers:

  • Portfolio expansion: Polymedic's therapeutic positions fill gaps in Laprophan's existing product range
  • Industrial and logistics reinforcement: Combined manufacturing capabilities enhance local production capacity
  • Distribution and service synergies: Overlapping commercial channels offer cost optimization opportunities
  • R&D pipeline development: Shared resources accelerate new molecule development

A Pattern of Transformative M&A Since 2020

This transaction represents the fourth pillar of a deliberate consolidation playbook executed since 2020:

  • 2024: Acquisition of 100% of Amanys Pharma (hospital segment and beta-lactam specialist)
  • 2024: Acquisition of 75% of Botanic Pharma (dietary supplements specialist)
  • 2026: Acquisition of 60% of Rivopharm (Swiss group focused on CNS and cardiovascular treatments)

The Combined Entity at a Glance

Post-acquisition (including Rivopharm), the Laprophan group would present the following profile:

  • Headcount: ~1,450 collaborators
  • Production sites: Four facilities across Morocco and Switzerland
  • Geographic reach: Direct and indirect commercial presence in 50+ countries
  • Regulatory portfolio: 1,300+ AMMs across 15 therapeutic areas
  • Annual production capacity: Exceeding 180 million units

Outlook and Conditions Precedent

Completion remains contingent on securing all necessary regulatory authorizations, principally the Competition Council's favorable opinion. No indicative closing calendar was communicated. Market observers will watch closely whether this deal triggers further consolidation among Morocco's mid-sized pharmaceutical players, as scale advantages become increasingly decisive in a sector facing rising regulatory complexity and pricing pressure.

Discussion (0)